NEZAM H AFDHAL, M.D.
Osteopathic Medicine in Boston, MA
License number
Massachusetts 71843
Category
Osteopathic Medicine
Type
Hepatology
Address
Address
110 Francis St. STE 8E, Boston, MA 02215
Phone
(617) 632-1069
Personal information
See more information about NEZAM H AFDHAL at radaris.comName
Address
Phone
59 9Th St, Charlestown, MA 02129
59 Pier 7, Charlestown, MA 02129
59 Constellation Wharf, Charlestown, MA 02129
59 Pier 7, Charlestown, MA 02129
106 9Th St, Charlestown, MA 02129
Professional information
Dr. Nezam H Afdhal, Boston MA - MD (Doctor of Medicine)
Specialties:
Gastroenterology, Transplant Hepatology
Address:
Beth Israel Deaconess Liver Center
110 Francis St SUITE 8E, Boston 02215
(617) 632-1070 (Phone)
110 Francis St SUITE 8E, Boston 02215
(617) 632-1070 (Phone)
Certifications:
Gastroenterology, 1993, Internal Medicine, 1991, Transplant Hepatology, 2006
Awards:
Healthgrades Honor Roll
Languages:
English, Farsi
Education:
Medical School
Columbia University College Of Physicians and Surgeons
Graduated: 1981
Columbia University College Of Physicians and Surgeons
Graduated: 1981
Nezam H Afdhal, Boston MA
Specialties:
Gastroenterologist
Address:
110 Francis St, Boston, MA 02215
Education:
Royal College of Surgeons in Ireland, School of Medicine - Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)*, American Board of Internal Medicine Sub-certificate in Transplant Hepatology (Internal Medicine)*
Nezam H Afdhal, Boston MA
Specialties:
Internal Medicine, Transplant Hepatology, Hepatology, Gastroenterology
Work:
Beth Israel Deaconess Medical Center
110 Francis St, Boston, MA 02215 Beth Israel Deaconess Medical Center
330 Brookline Ave, Boston, MA 02215
110 Francis St, Boston, MA 02215 Beth Israel Deaconess Medical Center
330 Brookline Ave, Boston, MA 02215
Education:
Royal College Of Surgeons In Ireland (1981)
Physician At Bidmc
Position:
Physician at BIDMC
Location:
Greater Boston Area
Industry:
Hospital & Health Care
Work:
BIDMC
-
Physician
Porcine Hepatocytes For Use In Treatment Of Disorders Characterized By Insufficient Liver Function
US Patent:
6610288, Aug 26, 2003
Filed:
May 24, 1996
Appl. No.:
08/653059
Inventors:
Albert Edge - Cambridge MA
J. Ryan Gunsalus - Boston MA
Nezam H. Afdhal - Charlestown MA
J. Ryan Gunsalus - Boston MA
Nezam H. Afdhal - Charlestown MA
Assignee:
Diacrin, Inc. - Charlestown MA
Trustees of Boston University - Boston MA
Trustees of Boston University - Boston MA
International Classification:
A01N 6300
US Classification:
424 932, 4241391, 4241841, 435325
Abstract:
Isolated porcine hepatocytes, isolated populations of such hepatocytes and methods for using the hepatocytes to treat subjects with disorders characterized by insufficient liver function are described. The porcine hepatocytes can be either hepatocytes isolated from adult, immature, or embryonic swine. The porcine hepatocytes can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e. g. , an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e. g. , by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine hepatocytes of the invention can be used to treat disorders characterized by insufficient liver function by administering the hepatocytes to a subject having such a disorder.
Methods Of Determining Resistance To Treatment For Hepatitis C Virus
US Patent:
2003001, Jan 16, 2003
Filed:
Sep 28, 1999
Appl. No.:
09/406997
Inventors:
ALBERT EDGE - CAMBRIDGE MA, US
NEZAM H. AFDHAL - CHARLESTOWN MA, US
NEZAM H. AFDHAL - CHARLESTOWN MA, US
International Classification:
C12Q001/70, G01N033/53, C12P021/06, A61K039/29
US Classification:
435/007100, 435/005000, 435/069100, 424/225100
Abstract:
Methods for identifying hepatitis C virus (HCV)-infected subjects responsive to treatment for HCV infection or unlikely to respond to treatment for HCV infection are described. The level of Th2 cytokines in the subject during treatment serves as an indicator of whether the subject is likely to respond to treatment for HCV, e.g., interferon treatment. An elevated level of at least one Th2 cytokine during treatment indicates that an HCV-infected subject is unlikely to respond to a treatment for HCV. A decreased level of at least one Th2 cytokine indicates that an HCV-infected subject is responsive to a treatment for HCV. In a preferred embodiment, IL-10 levels are detected to identify subjects responsive to or unlikely to respond to interferon treatment.